How Did Novo Nordisk's Modern Insulin Segment Perform in 3Q17?

In 3Q17, Novo Nordisk's (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.
Symbol: FOREX:AUDDKK